1925 West Field Court, Suite 300,
Lake Forest,
Illinois 60045
United States,
(847) 279-6100
www.akorn.com
Akorn, Inc. is a niche generic pharmaceutical company engaged in the development, manufacture and marketing of multi-source and branded pharmaceutical products in the areas of ophthalmology, antidotes, anti-infectives, and controlled substances for pain management and anesthesia in the United States and across the globe. Akorn, Inc. was founded in 1971 and is based in Lake Forest, Illinois.
| Year | ≤ '13 | '14 | '15 | '16 | '17 | '18 | T | |
|---|---|---|---|---|---|---|---|---|
| Buy (0.4/yr) | # | 3 | 2 | - | - | - | - | 5 |
| vol | $666M | $485M | $1.2B | |||||
| Sell (0.4/yr) | # | - | 2 | - | - | - | - | 2 |
| vol | $120M | $120M | ||||||
| 7 | ||||||||
| Financial | Deals |
|---|---|
|
Sign-up to View
|
2 |
| Legal | Deals |
|---|---|
|
Sign-up to View
|
2 |
|
Sign-up to View
|
1 |
| Buy | # | TOTAL |
|---|---|---|
| > $1B | Sign-up to View | |
| $100M to $1B | Sign-up to View | |
| < $100M | Sign-up to View | |
| TOTAL | Sign-up to View | |
| Largest |
Hi-Tech Pharmacal Co., Inc. $640M (2013-08-27) |
|
| Sell | # | Total |
|---|---|---|
| > $1B | Sign-up to View | |
| $100M to $1B | Sign-up to View | |
| < $100M | Sign-up to View | |
| Total | Sign-up to View | |
| Largest |
Aciex Therapeutics, Inc. $120M (2014-10-24) |
|
Akorn was acquired by Fresenius Kabi USA on April 24, 2017.
Akorn has acquired 5 companies of its own, including 3 in the last 5 years. A total of 1 acquisition came from private equity firms. It has also divested 2 assets.
Akorn’s largest acquisition to date was in 2013, when it acquired Hi-Tech Pharmacal for $640M. It’s largest disclosed sale occurred in 2014, when it sold Aciex Therapeutics to Nicox SA for $120M. Akorn has acquired in 4 different US states. The Company’s most targeted sectors include life science (40%) and medical products (40%).
When analyzing the life science sector as a whole, according to Mergr, in the last 3 years, there are 410 life science companies that have made at least 1 acquisition, 15 have acquired at least 5 companies, and 2 have acquired more than 10 companies. The most prolific strategic life science acquirer over the past 3 years is Eurofins Scientific SA, with 29 acquisitions. The most prolific private equity acquirer in the life science sector over the past 3 years is Ampersand Capital Partners with 5 platform acquisitions.
Join Mergr and gain access to Akorn’s M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the life science sector.
No obligation. Cancel anytime.
